EnteroMedics


 

homesitemapcontact us

   search

 

   
   
   
   

EnteroMedics® Inc. is the developer of VBLOC® vagal blocking therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, a first-in-class weight loss treatment for obesity and obesity related risk factors, such as high blood pressure or high cholesterol levels. VBLOC Therapy is a non-anatomy altering or restricting, reversible therapy that allows patients to safely lose weight by helping patients feel less hungry, reduce the amount of food eaten at a meal, and feel full longer in between meals.

NASDAQ: ETRM

 
 

3/02/2015
VBLOC Therapy featured in WebMD’s Future of Health hosted by Robin Roberts

more news >

   
   
   


VBLOC® Therapy, delivered via the Maestro ® System, is now approved by the Food and Drug Administration for weight loss in adults with a BMI of 40 to 45 kg/m2 or a BMI of 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels.*

learn more >

 


At EnteroMedics, partnerships are viewed as an excellent approach for achieving our business objectives, and we are interested in hearing from you.

learn more >

 

 


February 18, 2015
ETRM Fourth Quarter 2014 Earnings Call

January 14, 2015
EnteroMedics Company Update

learn more >

 

   
                 

   

* Individuals should have first tried to lose weight by diet and exercise in a supervised program within the last 5 years before receiving the Maestro System.